Angiotensin II Blockade Limits Tubular Protein Overreabsorption and the Consequent Upregulation of Endothelin 1 Gene in Experimental Membranous Nephropathy

Proteinuric renal diseases are associated with excessive renal synthesis of endothelin 1 (ET-1) either in experimental animals or humans. This has been interpreted as an upregulation of ET-1 gene in proximal tubular cells secondary to overreabsorption of an unusual amount of filtered proteins. Here we used a model of chronic proteinuria, passive Heymann nephritis (PHN), to localize the structure of the kidney responsible for excessive ET-1 expression and synthesis and to clarify whether drugs that reduce glomerular protein trafficking modified the distribution of ET-1 mRNA and the corresponding peptide in the kidney. PHN was induced in Sprague-Dawley rats after injection of rabbit anti-Fx1A antibody. Group 1 (n = 5) was untreated, group 2 (n = 5) was given daily the angiotensin-converting enzyme inhibitor lisinopril (40 mg/l) plus the angiotensin II receptor antagonist L-158,809 (50 mg/l) from day 7 – when rats were already proteinuric – to month 12. An additional group of normal rats (n = 5) was used as controls. Urinary excretion of ET-1 was significantly increased in PHN rats as compared with controls and normalized by the treatment. By in situ hybridization a weak signal for ET-1 mRNA was detectable in glomeruli, distal tubular segments, and proximal tubules of control kidneys. By contrast, a strong labeling was found in the kidneys of rats with PHN which was mainly localized to proximal tubules and renal interstitium. The pattern of renal ET-1-like immunoreactivity was remarkably consistent with ET-1 mRNA expression. In animals with PHN given the angiotensin II blocking therapy, the urinary excretion of proteins normalized, and the structural integrity of the kidney was well preserved. In the kidney tissue taken from these animals, both ET-1 mRNA and protein staining were quite comparable to controls. These data suggest a link between excessive protein tubular reabsorption and enhanced renal ET-1 in chronic nephropathies and provide a novel explanation for the renoprotective effect in vivo of drugs that, by blocking the biological activity of angiotensin II, reduce glomerular protein traffic and possible deleterious effects of excessive tubular protein overloading.

[1]  G. Remuzzi,et al.  The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  M. Kretzler,et al.  Regulation of endothelin production and secretion in cultured collecting duct cells by endogenous transforming growth factor-beta. , 1996, Endocrinology.

[3]  G. Remuzzi,et al.  Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. , 1996, Experimental nephrology.

[4]  G. Remuzzi,et al.  Glomerular protein trafficking and progression of renal disease to terminal uremia. , 1996, Seminars in nephrology.

[5]  G. Remuzzi,et al.  Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  G. Remuzzi,et al.  Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. , 1995, Current opinion in nephrology and hypertension.

[7]  J. S. Owen,et al.  Human high density lipoproteins stimulate endothelin-1 release by cultured human renal proximal tubular cells. , 1994, Kidney international.

[8]  N. Perico,et al.  Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. , 1994, Experimental nephrology.

[9]  Y. Tomino,et al.  Effects of enalapril on endothelin-1 and growth factor gene expression in diabetic rat glomeruli. , 1994, The Journal of laboratory and clinical medicine.

[10]  J. Keiser,et al.  Endothelin-1 mRNA in glomerular and epithelial cells of kidney. , 1993, The American journal of physiology.

[11]  Z. Konopski,et al.  Endothelin-1 stimulates human monocytes in vitro to release TNF-α , IL-1β and IL-6 , 1993, Mediators of inflammation.

[12]  I. Stamenkovic,et al.  Location of gp330/alpha 2-m receptor-associated protein (alpha 2-MRAP) and its binding sites in kidney: distribution of endogenous alpha 2-MRAP is modified by tissue processing. , 1993, European journal of cell biology.

[13]  E. Schiffrin,et al.  Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. , 1993, Hypertension.

[14]  N. Perico,et al.  Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. , 1993, Kidney international.

[15]  G. Rao,et al.  Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. , 1992, Biochemical and biophysical research communications.

[16]  F. Marumo,et al.  Messenger RNA expression and synthesis of endothelin-1 along rat nephron segments. , 1992, The Journal of clinical investigation.

[17]  W. Greenlee,et al.  In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. , 1992, The Journal of pharmacology and experimental therapeutics.

[18]  L. Navar,et al.  Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. , 1992, The American journal of physiology.

[19]  D. Campbell,et al.  Differential Regulation of Angiotensin Peptide Levels in Plasma and Kidney of the Rat , 1991, Hypertension.

[20]  M. Susin,et al.  Localization of endothelin-like immunoreactivity in rat kidneys. , 1991, The American journal of physiology.

[21]  N. Perico,et al.  Increased renal endothelin production in rats with reduced renal mass. , 1991, The American journal of physiology.

[22]  M. Shichiri,et al.  Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. , 1991, Kidney international.

[23]  S. Snyder,et al.  Endothelin: visualization of mRNAs by in situ hybridization provides evidence for local action. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Remuzzi,et al.  Age-related nephropathy and proteinuria in rats with intact kidneys exposed to diets with different protein content. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[25]  D. Northcote,et al.  Minimization of variation in the response to different proteins of the Coomassie blue G dye-binding assay for protein. , 1981, Analytical biochemistry.

[26]  M. Pfeffer,et al.  Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. , 1971, The Journal of laboratory and clinical medicine.

[27]  T. Edgington,et al.  Characterization and isolation of specific renal tubular epithelial antigens. , 1967, Journal of immunology.

[28]  H. W. Smith,et al.  THE RENAL CLEARANCES OF SUBSTITUTED HIPPURIC ACID DERIVATIVES AND OTHER AROMATIC ACIDS IN DOG AND MAN. , 1945, The Journal of clinical investigation.